Key result
Patients on SGLT2 inhibitors face ~21% 1-year CV death or HF hospitalization rate.
Why the study?
SGLT2 inhibitors reduce heart failure hospitalizations and cardiovascular death, but Hispanic/Latino patients and methamphetamine users have been under-represented in prior studies.
What is the rate of cardiovascular death and heart failure hospitalization within 12 months of starting SGLT2i therapy in an ethnically diverse heart failure population with a high prevalence of methamphetamine use?
Cohort (n=413)
No
What is the rate of cardiovascular death and heart failure hospitalization within 12 months of starting SGLT2i therapy in an ethnically diverse heart failure population with a high prevalence of methamphetamine use?
In an ethnically diverse safety-net heart failure cohort taking SGLT2 inhibitors, heart failure hospitalization rates decreased across all subgroups, though overall adverse cardiovascular event rates remained high (20.8% at 1 year) and were independently predicted by methamphetamine use, prior heart failure hospitalization, and reduced LVEF rather than race or ethnicity.
Answers are grounded in this paper and cite their sources.
Residual high event rates after SGLT2i identify high-risk HF subgroups for closer monitoring; extends real-world data to diverse populations with methamphetamine use but leaves open causality.
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been shown to decrease heart failure hospitalizations (HFHs) and cardiovascular (CV) death; however, Hispanic/Latino patients and methamphetamine (MA) users have been under-represented. PROJECT RATIONALE: The purpose of this retrospective study was to assess CV outcomes in the Central Valley region of California within 12 months of starting a SGLT2i. PROJECT SUMMARY: Overall, 413 patients were included, with non-White patients and MA users accounting for 72% and 27% of the population, respectively. The composite CV outcome occurred in 86 of 413 patients (20.8%), 22% of Whites and 19%-27% of non-Whites. Significantly reduced HFH rates were observed in the overall population and subgroups after 1 year of starting SGLT2i. Reduced left ventricular ejection fraction, prior HFH, and MA use predicted CV outcomes, though the retrospective nature of this analysis limits causal inference. TAKE-HOME MESSAGE: MA use, prior HFH, and reduced left ventricular ejection fraction predicted CV outcomes, irrespective of ethnicity.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) conducted a cohort in Heart failure (n=413). Sodium-glucose cotransporter 2 inhibitors (empagliflozin or dapagliflozin) was evaluated on Composite of cardiovascular death and heart failure hospitalization within 12 months. SGLT2 inhibitor-treated patients had a 20.8% 1-year CV death or HFH rate, predicted by prior HFH, methamphetamine use, and reduced LVEF.
Synapse has enriched 10 related papers. Consider them for comparative context: